Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

OVERSEAS REGULATORY ANNOUNCEMENT LEGEND BIOTECH UPDATES PIPELINE OF PRODUCT CANDIDATES

This announcement is made by the board of directors (the "**Board**") of GenScript Biotech Corporation (the "**Company**") pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Legend Biotech Corporation ("**Legend Biotech**"), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the "**SEC**") in relation to its updated pipeline of product candidates (the "**Pipeline**"). For details, please refer to the attached Pipeline. The attachment is the full Form 6-K as published on the SEC's website available at https://www.sec.gov/Archives/edgar/data/1801198/000115752322001713/0001157523-22-001713-index.htm.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 8 December 2022

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

** For identification purposes only*

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

Date of Report: December 8, 2022

Commission File Number: 001-39307

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)

2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Legend Biotech Reports Updated Pipeline of Product Candidates

Legend Biotech Corporation (the "**Company**") is updating its pipeline of product candidates, as set forth in Exhibit 99.1.

This Form 6-K, including Exhibit 99.1 hereto, is hereby incorporated by reference into the Registration Statements of the Company on Form F-3 (File Nos. 333-257625 and 333-257609) and the Company's Registration Statement on Form S-8 (File No. 333-239478).

Cautionary Note Regarding Forward-Looking Statements

Statements in this report on Form 6-K about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company's strategies and objectives; statements relating to CARVYKTI®, including the Company's expectations for CARVYKTI®; statements about submissions for cilta-cel to, and the progress of such submissions with, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Chinese Center for Drug Evaluation of National Medical Products Administration (CDE) and other regulatory authorities; and statements about the Company's pre-clinical and clinical product candidates, such as the anticipated timing of, and our ability to progress, pre-clinical projects and clinical trials, the submission of Investigational New Drug (IND) applications to, and maintenance of such applications with, regulatory authorities, the ability to generate, analyze and present data from clinical trials, and potential indications for, and benefits of, the Company's product candidates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. The Company's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to the Company's patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the "Risk Factors" section of the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2022. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Form 6-K as anticipated, believed, estimated or expected. Any forward-looking statements contained in this Form 6-K speak only as of the date of this Form 6-K. The Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

EXHIBIT INDEX

Exhibit	Title
99.1	Pipeline

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LEGEND BIOTECH CORPORATION

Date: December 8, 2022

By: /s/ Ying Huang
Name: Ying Huang, Ph.D.
Title: Chief Executive Officer

Global | US | China

Preclinical	Phase 1		Phase 2	Phase 3
GASTRIC, ESOPHAGEAL & PANCREATIC‡ **(CLAUDIN 18.2)** Autologous	**GASTRIC, ESOPHAGEAL & PANCREATIC†** **(CLAUDIN 18.2)** Autologous NCT04467853	**RRMM (BCMA)** **LEGEND-2†** Autologous NCT03090659	**RRMM (BCMA)*** **CARTIFAN-1** Autologous NCT03758417	**RRMM (BCMA)*** **1-3 Prior Lines** **CARTITUDE-4** Autologous NCT04181827
SCLC‡ **(DLL3)** Autologous	**MM†** **(BCMA)** Allogeneic – CAR-NK NCT05498545	**NHL† /ALL†** **(CD19 X CD20 X CD22)†** Autologous NCT05318963 NCT05292898	**RRMM (BCMA)*** **CARTITUDE-1** Autologous NCT03548207	**NDMM (BCMA)*** **Transplant Not Intended** **CARTITUDE-5** Autologous NCT04923893
NSCLC **(GPC3)** Autologous	**MM†** **(BCMA)** Allogeneic – CAR-γδ T NCT05376345	**HCC†** **(GPC3)** Autologous NCT05352542	**MM (BCMA)*** **CARTITUDE-2** Autologous NCT04133636	**NDMM (BCMA)*** **Transplant Eligible** **CARTITUDE-6** Autologous NCT05257083
COLORECTAL **(GCC)** Autologous				
AML **(CLL1/CD33)** Allogeneic				

The safety and efficacy of the agents and/or uses under investigation have not been established.
There is no assurance that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Additionally, as some programs are still confidential, certain candidates may not be included in this list.

*In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson.
†Phase 1 IIT in China.
‡IND applications have been cleared by the U.S. FDA.

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCMA, B-cell maturation antigen; DLL3, delta-like ligand 3; GPC3, glypican-3; GCC, guanylyl cyclase C; HCC, hepatocellular carcinoma; IIT, investigator-initiated trial; MM, multiple myeloma; ND, newly diagnosed; NHL, non-Hodgkin lymphoma; NSCLC, non small cell lung cancer; RRMM, relapsed or refractory multiple myeloma; SCLC, small cell lung cancer.